Magnetocardiography in the Accurate Identification of Myocardial Infarction

Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18-79
SponsorQilu Hospital of Shandong University

About this trial

Magnetocardiography (MCG) is a promising noninvasive and accurate method for detecting myocardial infarction. Although progress has been made in this area, there is a lack of studies using up-to-date examination instruments for the calibration of MCG analysis. This is a prospective single-center study aiming to build accurate analytical models of MCG to detect myocardial infarction. Myocardial infarction are diagnosed by electrocardiogram, biomarkers (high-sensitivity cardiac troponin, etc), or non-invasive imaging (cardiac magnetic resonance or single-photon-emission tomography). Myocardial infarction is also quantified by cardiac magnetic resonance or single-photon-emission tomography. Healthy volunteers and chest pain patients who will receive electrocardiogram, biomarkers (high-sensitivity cardiac troponin, etc), or non-invasive imaging (cardiac magnetic resonance or single-photon-emission tomography) examination will be enrolled in this study.

Eligibility criteria

Qualifiers

Age 18-79 years old;

No history of cardiovascular disease (coronary heart disease, structural heart disease, arrhythmia, heart failure, stroke, pulmonary embolism, aortic dissection, etc.), no cardiovascular risk factors (hypertension, diabetes, hyperlipidemia). For people over 65 years old, those with hypertension or hyperlipidemia, but with well-controlled blood pressure and lipid levels, taking no more than 2 drugs, and echocardiography showing no left ventricular hypertrophy, can be included;

The electrocardiogram is normal, and the cardiac ultrasound is basically normal in the past 1 year (mild valvular regurgitation can be included).

Sign the informed consent.

Disqualifiers

Those who with acute or chronic respiratory diseases;

Those who with obvious abnormality of liver or kidney function;

Those who with endocrine diseases such as abnormal thyroid function;

Those who with anemia or other blood diseases;

Trial design

Treatments tested in this trial

  • Magnetometer

Treatment groups

3,841 Participants
are divided into 2 treatment groups

Sponsors and collaborators

Qilu Hospital of Shandong University

Lead sponsor

Chongqing Emergency Medical Center

Collaborator

Weifang People's Hospital

Collaborator

Linyi People's Hospital

Collaborator

Weihai Central Hospital

Collaborator

Jining First People's Hospital

Collaborator

The First Affiliated Hospital with Nanjing Medical University

Collaborator

Second Affiliated Hospital, School of Medicine, Zhejiang University

Collaborator

First Affiliated Hospital Xi'an Jiaotong University

Collaborator

Guangdong Provincial Hospital of Traditional Chinese Medicine

Collaborator

Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University

Collaborator

Qianfoshan Hospital

Collaborator

Heze Municipal Hospital

Collaborator

First People's Hospital of Hangzhou

Collaborator